<DOC>
	<DOCNO>NCT01243580</DOCNO>
	<brief_summary>Pharmacokinetics safety AG200-15 two consecutive cycle therapy evaluate .</brief_summary>
	<brief_title>AG200-15 Transdermal Contraceptive Delivery System ( TCDS ) Levonorgestrel Ethinyl Estradiol</brief_title>
	<detailed_description>This open-label study comprise two part . Part I single-arm , run-in cycle AG200-15 administered subject 21-7 day regimen ( three consecutive week patch wear follow patch-free week ) . Part II employ crossover design subject randomly assign one two treatment sequence . Each sequence include AG200-15 oral contraceptive ( Ortho-Cyclen® ) describe : Sequence 1 : AG200-15 ( Period 1 ) follow oral contraceptive , Ortho-Cyclen® ( Period 2 ) ; Sequence 2 : Oral contraceptive , Ortho-Cyclen® ( Period 1 ) follow AG200-15 ( Period 2 ) Both AG200-15 Ortho-Cyclen® administer 21-7 day regimen ( three consecutive week drug-taking follow drug-free week ) . Duration treatment Period 28 day ( one cycle therapy ) .</detailed_description>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Healthy woman , age 1845 Body mass index ( BMI ) ≥18 ≤32 , weight ≥ 110 lb . Willing use nonhormonal method contraception risk pregnancy , OR already undergone previous bilateral tubal ligation hysterectomy Willing refrain use alcohol grapefruit juice 48 hour prior completion treatment period Known suspect pregnancy ; Lactating woman Significant skin reaction transdermal preparation sensitivity surgical / medical tape Any disease may worsen hormonal treatment ( cardiovascular , liver , metabolic ) Use contraceptive method study medication Smokers</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>PK safety</keyword>
	<keyword>Pharmacokinetic profile ( PK ) safety</keyword>
</DOC>